CGTLive’s Weekly Rewind – September 16, 2022
Review top news and interview highlights from the week ending September 16, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. IL13Rα2 Universal CAR T Therapy Shows Antitumor Activity in Recurrent Glioma
MT026 had an overall response rate of 83.3% in a first-in-human, investigator-initiated trial.
2. Phase 1 Clinical Trial Will Assess CAR-T With Genetic and Epigenetic Reprogramming for Solid Tumors
Improved functional activity compared to ROR-1-targeted CAR-T therapies without the 2 forms of reprogramming was demonstrated in preclinical studies.
3. Ide-Cel to Be Evaluated in Newly Diagnosed Multiple Myeloma
The announcement comes after positive top-line results in the ongoing KarMMa-3 study.
4. ICER Throws Support Behind Clinical, Cost Value of Hemophilia Gene Therapies in Draft Report
A substantial benefit noted for EtranaDez and val-rox is that they are delivered as a single-dose.
5. Weijia Fang, MD, and Tianhang Luo, MD, on EpCAM-Targeted CAR-T Therapy in Advanced Colorectal and Gastric Cancer
Fang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.
